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Abstract
An ideal surface for implantable glucose sensors would be able to evade the events leading to
chronic inflammation and fibrosis, thereby extending its utility in an in vivo environment.
Nafion™, a perfluorinated ionomer, is the membrane material preferred for in situ glucose
sensors. Unfortunately, the surface properties of Nafion™ promote random protein adsorption and
eventual foreign body encapsulation, thus leading to loss of glucose signal over time. Details of
the techniques to render Nafion™ nonprotein fouling are given in a previous article [T. I. Valdes
et al., Biomaterials 29, 1356 (2008)]. Once random protein adsorption is prevented, a biologically
active peptide can be covalently bonded to the treated Nafion™ to induce cellular adhesion.
Cellular responses to these novel decorated Nafion™ surfaces are detailed here, including cell
viability, cell spreading, and type I collagen synthesis. Normal human dermal fibroblasts (NHDFs)
were cultured on control and modified Nafion™ surfaces. Findings indicate that Nafion™
modified with 10% 2-hydroxyethyl methacrylate and 90% tetraglyme created a nonfouling surface
that was subsequently decorated with the YRGDS peptide. NHDFs were shown to have exhibited
decreased type I collagen production in comparison to NHDF cells on unmodified Nafion™
surfaces. Here, the authors report evidence that proves that optimizing conditions to prevent
protein adsorption and enhance cellular adhesion may eliminate fibrous encapsulation of an
implant.
I. INTRODUCTION
One of the main obstacles for the long-term implantation of some medical devices is the
creation of a fibrotic capsule around the implant-tissue interface of the device. This dense,
collagenous capsule is not detrimental to some devices, but drastically limits the function of
implantable biosensors, which are dependent on the influx of analytes to or from the surface.
Increasing the lifetime of an implantable glucose biosensor, for example, would be quite
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advantageous for diabetic patients, decreasing their chances of related complications, such
as blindness, kidney failure, heart disease, among others.1,2
In the development of a fully implantable glucose sensor, several different types of
membrane materials have been utilized, including polytetrafluoroethylene,3–10
polyvinylchloride,11–17 cellulose or cellulose acetate,15,17–29 and polyurethane.8,28,30–41
Included in this list is the use of the perfluorinated ionomer, Nafion™ (Dupont, Inc.).
Nafion™ is a perfluorinated ionomer, and as such, is highly ion conductive and can function
as a cation exchange polymer. In addition, like Teflon, Nafion™ is extremely resistant to
chemical attack. For a glucose sensor, Nafion™ serves four purposes, namely, (a) to reject
negative molecules; (b) to physically protect the glucose oxidase enzyme that drives the
chemical reaction of the biosensor (acting as a physical barrier); (c) to act as a glucose
transport-limiting membrane, thereby reducing the oxygen requirement of the biosensor; and
(d) to maintain some level of biocompatibility, especially after curing the Nafion™
membrane.42,43 As has been stated in literature, when comparing materials for the
construction of glucose biosensors, Nafion™ based glucose sensor provides the best long
term response stability.17 There are numerous publications that utilize Nafion™ in the
design of a glucose biosensor and the most recent publications are listed.44–93
Like other coatings, however, Nafion™ is subject to the changes that occur in the
subcutaneous tissues once an implant is in place. The cascade of events leading to fibrosis
has been described previously.94 Briefly, after protein adhesion and the start of the acute
inflammatory stage, chronic inflammation begins typically approximately 3–5 days after
implantation. For a subcutaneous device, such as a biosensor, skin fibroblasts begin to
secrete chronic inflammatory cytokines, the most abundant having been found to be
TGFβ-1.95 Once exposed to TGFβ, myofibroblasts will differentiate from quiescent
fibroblasts, and the production of type I collagen begins. Type I collagen is the most
prominent component of fibrotic tissue and has been shown to be a main component of what
is known as the “foreign body reaction.”
Various surface modification strategies have been utilized in an attempt to modulate the
inflammatory response. One attempt has been to eliminate surface “fouling” or the random
and unlimited adsorption of proteins to a surface. To this end, one of the most prominent
techniques has been the use of polyethylene glycol (PEG) coated surfaces as detailed in
Refs. 96–100 to name a few. Although PEG is effective in preventing nonspecific protein
adsorption, its nonfouling character is dependent on the surface chain density and can be
subject to damaged by oxidants.101 The use of plasma deposition of ethylene glycol
dimethyl ether or “oligoglymes” has been shown as an alternative to materials that utilize
PEG in their design.102,103 Although these strategies have been shown to be effective in
vitro, studies have shown that after 4 weeks of implantation, fibrous capsules around coated
and uncoated implants were virtually the same.104,105
Research in the area of biologically active surfaces has included much work with the
ubiquitous peptide sequence, arginine-glycine-aspartic acid or RGD, as it is known for its
properties for cell adhesion. The RGD site has been identified in many extracellular matrix
proteins, including vitronectin, fibrinogen, collagen, laminin, osteopontin, and tanascin, and
is known to bind to approximately half of all identified integrins.106 Little research has been
done in the use of a plasma method to functionalize surfaces. In particular, little research has
been conducted to modulate the fibroblast response.
In a previous publication, we detailed the surface modification of the perfluorinated
ionomer, Nafion™. Briefly, by using a radio frequency glow discharge deposition (RFGDD)
method, surfaces were modified by using a combination of two monomers, thereby creating
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a new surface able to prevent random protein adsorption and concomitantly be reactive
enough to display a biologically active peptide.44 This goal was accomplished by mixing (1)
tetraethylene glycol dimethyl ether (tetraglyme) and (2) 2-hydroxyethyl methacrylate
(HEMA) at different ratios. The first monomer provided a nonfouling base, and the second
monomer provided the reactive hydroxyl groups that were necessary for the subsequent
chemical attachment of the YRGDS peptide, a known cell adhesion ligand. In this article,
we detail the cellular response to these surfaces; metrics used included cell viability,
spreading, engagement of integrin receptors, and type I collagen synthesis.
II. MATERIALS AND METHODS
A. Preparation of surface coatings and surface analysis
Details of the synthesis of surfaces can be found in Ref. 44. Plasma polymerization, or
polymerization initiated by a partially ionized gas generated by the RFGDD method, is
widely used for preparing coatings and insulating layers.107
Several variations of surface coatings were created using two base monomers individually or
by combining the two at different concentrations. They were (1) tetraethylene glycol
dimethyl ether (tetraglyme, Aldrich Catalog No. 172405), known for its nonfouling
characteristics,102 and (2) HEMA (PolySciences Inc., ophthalmic grade),108 known for its
biocompatibility and available reactive hydroxyl groups. Combinations used were as
follows: pure tetraglyme, 2.5% HEMA with 97.5% tetraglyme; 5% HEMA with 95%
tetraglyme, 10% HEMA with 90% tetraglyme; and pure HEMA. Once prepared, surfaces
were evaluated for the degree to which they were able to repel serum proteins, such as
albumin and fibronectin. Surfaces were then characterized for their hydroxyl group content
and were assessed for their ability to covalently bind a biological peptide, YRGDS. Method
details are outlined elsewhere.44 Briefly, the peptide was radiolabeled using the Iodobead™
method and was covalently bound to available surface hydroxyl groups using 1,1′-
carbonyldiimidazole (CDI)(Sigma) in anhydrous acetone. Once bound, YRGDS bound
peptide was quantified via a gamma counter and YRGDS peptide linked to modified
Nafion™ surfaces was calculated (ng/cm2).44 It was observed that the 10% HEMA, 90%
tetraglyme modified surfaces provided the lowest protein adsorption with a sufficient
amount of available hydroxyl groups. In addition, 10% HEMA surfaces were found to
exhibit the most cell spreading (see details below). Therefore, all cellular experiments
reported here were carried out on either 10% HEMA–90% tetraglyme surfaces or
unmodified Nafion™ and compared to various control surfaces (tissue culture surfaces).
B. Adhesion assays to Nafion™ and modified Nafion™ materials
NHDFs (Cambrex Inc., Catalog No. 2511) were grown on T75 flasks (Corning). Low
glucose Dulbecco's modified Eagle's medium was made from powder (Sigma Catalog No.
D-2902 (no phenol red) or D-5523 (with phenol red dye)] and supplemented with 1%/
streptomycin and 3.7 g/l of sodium bicarbonate. The pH of the medium was 7.2 and was
maintained constant with (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer
(Invitrogen Inc.), which was added to the medium at a final concentration of 20 mM. The
medium was sterilized by filtration (0.2 μm filter, Stericups, Millipore) and then
supplemented with 10% fetal bovine serum (FBS), as needed to grow the cells. Following
sterilization under an UV light for 10 min, custom chambers containing Nafion™,
tetraglyme-coated Nafion™, or tetraglyme-HEMA coated Nafion™ were exposed to either
(1) a protein solution containing bovine serum albumin (100 μg/ml), (2) a protein solution
containing fibronectin (100 μg/ml), (3) a 10% serum solution in low glucose media, or (4)
were covalently decorated with the YRGDS peptide, as discussed in Ref. 44.
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After 24 h, surfaces were rinsed three times with sterile phosphate buffered saline (PBS)
(pH=7.2) and NHDF cells were concentration of 10 000 cells/cm2 in the custom chambers
for a period of either 4 or 24 h (for unmodified Nafion™ as well as TCPS) and for 24 h for
modified surfaces (tetraglyme and YRDGS-decorated surfaces). Cell concentrations were
quantified on various surfaces via the use of an epifluorescence microscope (Zeiss, Inc.)(10×
objective). To clearly visualize NHDF cells, the dual Live/Dead™ stain system (L3224
Molecular Probes, Inc.), consisting of SYTO 10 (green fluorescent nucleic acid “Live” stain)
and ethidium homodimer-2 (red fluorescent nucleic acid “dead” stain), was used. Direct
visualization of Live/Dead™ stained cells allowed a direct cell count enumeration and an
estimate of the area of cell spreading. Photographs were taken of at least 3 spots on one well
(4 wells/membrane, on two membranes per surface type) using a charge coupled device
camera and MAGNAFIRE image capture software. Adhesion of cells was then analyzed for
statistical differences between groups [using a two-factor a one-way analysis of variance
(ANOVA)] in the unmodified surfaces and between groups in the modified surfaces. In
addition, a single unmodified group (10% serum group) and a single modified group (10%
HEMA) were compared to check for statistical differences between the number of cells
adhered.
C. Immunocytochemistry for actin and paxillin
The ability of cells to sense and respond appropriately to changes in their immediate
external environment is dictated by the engagement of cell integrin receptors to an adhesion
ligand. Changes in the Nafion™ substrate may lead to changes in cell signaling mechanisms
that can be examined by immunocytochemical techniques. Two relevant intracellular
proteins were chosen: actin microfilaments and paxillin. Actin, a 43 kD protein, is the most
abundant protein in typical eukaryotic cells, accounting for approximately 15% of total
protein. Actin filaments are typically associated with the formation of the cytoskeleton.
Paxillin, a 68 kD protein, is an “adaptor” protein that facilitates optimal signal transduction
through its ability to recruit multiple intermediates of specific signaling pathways to specific
regions within the cell.109 Once these are recruited, proper signaling mechanisms can alter
complex events within cells, such as changes in gene expression and reorganization of the
cytoskeleton.
Three types of surfaces were examined, namely, a control surface–tissue culture chamber
slide (TCCS)(Nunc, Inc.), an unmodified Nafion™ surface, and a 10% HEMA modified
Nafion™ surface. Unmodified Nafion™ and TCCS received an overnight 10% serum
treatment at 37 °C. Surfaces coated with 10% HEMA were further modified with YRGDS
peptide, as outlined in Ref. 44. After rinsing surfaces with sterile PBS, a cell suspension was
used to submerge the Nafion™ membranes; cell suspensions were designed to produce a
plated concentration of 10 000 cells/cm2. Cells were left in contact with the surface samples
for 24 h in a CO2 incubator at 37 °C in serum-free media. Cells were then fixed with a 2%
paraformaldehyde solution, rinsed with PBS, blocked with a 10% FBS solution (in PBS),
and incubated with a primary antibody prepared in 5% FBS in PBS for 1 h at room
temperature. Primary antibodies were anti-α-actin (Sigma, Catalog No. A2066) and anti-α-
paxillin (BD Pharmingen Catalog No. 610051). Surfaces were then rinsed with PBS three
times and incubated with a 5% FBS solution containing two different secondary antibodies.
To visualize paxillin, a fluorescently labeled goat antimouse secondary antibody was chosen
(Molecular Probes, AlexaFlour 594, A-11005). To stain for actin, a fluorescently labeled
goat antirabbit secondary antibody was chosen (Molecular Probes, AlexaFlour 488,
A11008). Images were collected using an epifluorescence Zeiss microscope (40× objective
lens) and MAGNAFIRE image capture software. For actin, a fluorescein isothiocyanate
filter (Abs=495 nm; Em=520 nm) was used. For paxillin, a Texas red filter was used
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(Abs=583 nm; Em=603). Single-color images were collected separately and then merged
into one image using the MAGNAFIRE software.
D. Proliferation assays
Proliferation of NHDFs was carried out on three different surfaces: unmodified Nafion™
(with and without preadsorbed protein), 10% HEMA modified Nafion™, and a control
surface, TCPS. Proliferation of NHDF on these surfaces was assessed via Cell Titer 96®
Aqueous One Solution Cell Proliferation Assay (Promega, Inc.) or via direct visualization of
unmodified Nafion™ surfaces using the Live/Dead stain and IMAGEJ as outlined above.
The Cell Titer 96 assay is a colorimetric method, containing a tetrazolium compound [3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt; MTS (a)] and an electron coupling reagent [phenazine ethosulfate (PES)]. As
described by the manufacturer, the MTS tetrazolium compound (Owen's reagent) is
bioreduced by cells into a colored formazan product that is soluble in tissue culture medium.
The PES was believed to interfere with unmodified Nafion™ surfaces since absorbance
levels remained constant, despite a large number of cells on the surface (as verified by Live/
Dead stain).
Nafion™ surfaces were prepared as outlined above (unmodified with 10% serum or no other
protein, or YRGDS-modified 10% HEMA surfaces). Control TCPS received no prior
protein treatment. Fibroblast cells were plated at 20 000 cells/well (10 000 cells/cm2 in 500
μl) in phenol red-free media (containing 10% serum). Phenol red-free media were chosen to
avoid any potential interference with the colorimetric change in the Cell Titer assay. 4 h
after plating (day 0), two wells per surface type received 100 μl of Cell Titer assay and were
returned to 37 °C for 1 h. Contents of each well's cell suspension were transferred to
standard 24-well plates and read using a fluorescent plate reader at 490 nm wavelength.
Exactly 24 h later, the medium in each remaining well was replaced with fresh, serum-free
medium and Cell Titer 96 was added. This step ensured that evaporation of the medium was
minimized and that assays were performed on a full 500 μl to correspond to the standard
calibration. This process was repeated again until day 4. Cell Titer 96 assay absorbance
values were correlated with cell numbers using a standard curve, made with serum-free
media, using the same type of TCPS plate (Falcon, BD). A similar procedure was carried out
with unmodified Nafion™ surfaces, except that cells were counted using the Live/Dead
stain.
E. Quantification of type I collagen
Quantification of type I collagen was carried out because it is known to be the main
component of a fibrotic capsule that eventually surrounds an implant. Collagen synthesis has
been found to increase in renal fibroblasts in the presence of IL-1 (Ref. 110) and ascorbic
acid.111,112 Thus, in order to discern if differences in surface chemistry would modulate the
synthesis of collagen, cells on unmodified and 10% HEMA modified Nafion™ were
supplemented with IL-1, ascorbic acid, glucose oxidase, lipopolysaccharide (LPS), H2O2, or
were left “blank,” indicating no serum was added to the cell culture medium.
Enzyme linked immunosorbent assay (ELISA) assays for the procollagen molecule was
performed using the Metra® CICP (Quidel Corp.) assay. Collagen, a triple-helical molecule
that forms the fibrous framework of all connective tissues, is synthesized as procollagen, a
larger precursor molecule. Procollagen consists of mature collagen with extension peptides
at both the amino and the carboxy termini. These extension peptides, or “propeptides,” are
cleaved from the collagen molecule by specific proteases prior to the incorporation of
collagen into a growing collagen fibril. The release of these peptides into the cell culture
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media provides a stoichiometric representation of the production of collagen in a cell culture
environment.
Unmodified Nafion™ and 10% HEMA modified Nafion™ surfaces were prepared and
placed in fabricated six well plates. Surfaces were then either (a) incubated with a 10%
serum (in media) solution overnight (for unmodified Nafion™) or (b) reacted with 200 μg/
ml YRGDS via CDI chemistry, as previously explained.44 The next day, cells were plated in
two replicate wells at a density of 20 000 cells/well for the unmodified Nafion™ samples or
90 000 cells/well on YRGDS-modified surfaces (1% serum solution in the medium). 24 h
later, wells were rinsed twice with PBS, and the serum-free medium was added to make the
cells quiescent. The following day, the procollagen “test” assay medium was added. Table I
summarizes all substances added to cells on the different substrates and their respective
concentrations. Prior to performing these experiments, the toxicity of all agents was tested at
various concentrations and no change in the cell number was observed.
Once the cells were exposed to control or test medium for 24 h, certain cell culture
supernatants were collected and frozen at –80 °C until the ELISAs were carried out. Cells
still in culture wells were then quantified using either the Cell Titer 96 assay (Promega) or
counted directly by staining with Live/Dead stain (Molecular Probes, Invitrogen Corp.). In
this way, ELISA assays can be reported on a proprotein “per cell” basis, tracking exactly the
amount of extracellular protein produced per fibroblast cell. Briefly, the medium from
control wells or wells with Nafion™ samples was placed in the Metra® CICP type I
collagen assay (sandwich ELISA), with the preadsorbed capture antibody for 1 h. Plates
were washed with the provided reagents and incubated with a second detection antibody.
Provided reagents were added according the manufacturer's directions. ELISA plates were
read on a fluorimeter plate reader (Abs=405 nm).
III. RESULTS AND DISCUSSION
Cells were quantified on Nafion™ and modified Nafion™ surfaces. Adhesion assays were
instrumental in determining the number of cells per cm2 that adhered to the different
Nafion™ substrata, the viability/survival of the cells on the substrata, and degree of cell
spreading. Figure 1 shows the average number of adherent cells per area (cm2) on
unmodified Nafion™ surfaces. Each bar graph represents the average of eight wells (as
made in a custom chamber). These data are for the total adherent cells, both live and dead.
Cells attached after 4 h to Nafion™ pretreated with either 10% serum or fibronectin were
8259 and 8730 cells/cm2, respectively. Similar values were seen after 24 h of plating. This
was not a surprising result, as fibronectin is rich with adhesive peptides such as RGD. Serum
contains fibronectin as well as vitronectin. Bovine serum albumin, on the other hand,
adhered 1602 cells/cm2 4 h after plating and 5248 cells/cm2 after a 24 h period. Control
surfaces (TCPS) attached ~5000 cells/cm2 after 4 h and ~9000 cells/cm2 after 24 h.
Adherent cells were examined for their viability as a function of the different proteins pre-
exposed to the Nafion™ membranes (Table II). At either 4 or 24 h, the viability was greatest
on the Nafion™ membranes pre-exposed to fibronectin, followed by albumin and 10%
serum. Untreated TCPS exhibited the lowest viability.
Figure 2 shows the typical morphology of NHDF at a 4 and 24 h time point. At the 4 h time
period, we note a marked increase in cell numbers on surfaces preadsorbed with 10% serum
as opposed to albumin preadsorbed surfaces. After 24 h, we note no differences from the 4 h
data in the morphology of cells plated on surfaces preadsorbed with albumin. Cells plated on
both fibronectin exposed Nafion™ surfaces and untreated TCPS assumed a longer shape in
comparison to cells on Nafion™ surfaces preadsorbed with 10% serum. The degree to which
NHDF spread on was calculated using IMAGEJ. Figure 3 displays the area of cell spreading
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on Nafion™ surfaces preadsorbed with different proteins as well as untreated TCPS. Cells
plated on Nafion™ preadsorbed with 10% serum had an average spread area approximately
four times greater than that of cells plated on Nafion™ preadsorbed with albumin. There is a
decrease in the area of cell spreading from 4 to 24 h on surfaces preadsorbed with
fibronectin and on TCPS, as can be seen in Fig. 2.
Adhesion assays were also carried out on the modified Nafion™ surfaces. These surfaces
were prepared as outlined in Ref. 44 by covalently linking the YRGDS peptide via CDI
chemistry. The amount of YRGDS on these surfaces was a function of the amount of bulk
fluid (20 or 200 μg/ml) and was also dependent on the amount of hydroxyl groups that were
obtained from the mixing of tetraglyme and HEMA at different ratios, as described in Ref.
44. NHDFs were then plated onto YRGDS-modified Nafion™ surfaces at 10 000/cm2.
Figure 4 shows the average number of cells adhering per cm2 to Nafion™ surfaces
presenting increasing amounts of available hydroxyl groups and covalently decorated with
YRGDS at two different surface densities. Regardless of YRGDS level used, more peptide
should be coupled to the HEMA treated Nafion™ in a hydroxyl percent dependent trend.
Yet, at the lower peptide concentration, NHDF cells attached in similar amounts on all
HEMA treated Nafion™, except for pure HEMA modified surfaces, which showed lower
adherent cell counts.
At higher concentrations, the most adherence was seen on surfaces modified with 2.5%
HEMA, and a gradual increase in adhesion was observed with increasing HEMA
concentrations. ANOVA was conducted in order to discern any statistical differences
between surfaces adhered with 10% HEMA versus surfaces modified with 2.5%, 5%, and
pure HEMA for an adhesion period of 24 h and bulk peptide concentrations of 20 and 200
μg/ml. The 10% HEMA surfaces were chosen for this analysis as they are the subject of
subsequent tests described in this article (collagen synthesis ELISA, proliferation assays,
etc.). The p-values obtained from the analysis of the 20 μg/ml data indicate no statistically
significant differences between 10% and 2.5% modified HEMA surface (p=0.07), between
10% and 5% HEMA (p=0.64), or between 10% HEMA and pure HEMA (p=0.30). The p-
values obtained from the analysis of the 200 μg/ml data also indicated no statistically
significant differences between 10% and 2.5% modified HEMA surface (p=0.12), between
10% and 5% HEMA (p=0.06), and a between 10% HEMA and pure HEMA (p=0.15).
When comparing the values obtained between the lower and higher bulk peptide
concentrations, we note that higher bulk peptide concentration does not always correlate
with an increase in cell adhesion. For example, at the 200 μg/ml bulk peptide concentration,
5% and 10% HEMA surfaces exhibit approximately a 20% and 13% decrease (respectively)
in cells adhered/cm2 when comparing to adherent cells/cm2 at the lower peptide
concentration. Surfaces modified with 2.5% HEMA and pure HEMA did not exhibit the
same pattern but showed higher cell adhesion with higher bulk peptide concentration.
Surfaces modified with 2.5% HEMA had a 23% increase in cell adhesion at 200 μg/ml bulk
peptide concentration and pure HEMA had 53% higher cell adhesion. Statistical analysis
between all groups indicated no significant differences between any of the lower and higher
peptide concentrations (p=0.10).
To test the degree to which cells adhere to the modified surfaces on the 10% HEMA
surfaces (which were chosen for subsequent experiments), cells were plated at increasing
densities. Figure 5 shows adherent live/dead cells as a function of the cell seeding
concentration. At all seeding densities, the majority of cells that did attach remained viable.
At all seeding densities, about ~50% of cells attach. Increasing the seeding to 200 000 cells/
well) only increased the number of cells attached by 65%, but with a noted increase in the
number of dead cells. Viability of cells plated on 10% HEMA modified Nafion™ and at the
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two different covalently bound peptide concentrations is given in Table III. From these data,
we see high survival rates on all surfaces at both peptide concentrations (>88%–98%
survival). The morphology of cells adhered to these HEMA treated-peptide presenting
Nafion™ substrata was also assessed and quantified (Fig. 6).
To better understand the degree of integrin engagement in the adhesion studies, the
formation of actin cytoskeleton and the activation of paxillin in NHDF cells was measured
by immunocytochemistry. As stated above, following cell adhesion experiments, surfaces
were screened for optimal cell adhesion and spreading. Surfaces modified with 10% HEMA
exhibited the least amount of protein adsorption but the most cell adhesion, a goal that was
set at the start of the project (i.e., a nonfouling coating, able to have bioactive properties) at
the lower, 20 μg/ml, peptide concentration. Figure 7 depicts immunocytochemistry
experiments done on unmodified Nafion™, 10% HEMA modified Nafion™, and a control
surface (tissue culture chamber slide-TCCS). The last row, termed “merged,” refers to the
overlay of the two photographs. It can be discerned from these photographs that paxillin was
clearly activated at the points of focal contact on all surfaces, but paxillin production was
more pronounced on control surfaces. Control TCCS and unmodified Nafion™ surfaces
preadsorbed with 10% serum saw the most spreading of cells, while surfaces containing the
YRGDS peptide at 20 and 200 μg/ml concentrations spread less. A single-factor ANOVA
was utilized to compare the spreading between 10% serum on unmodified surfaces versus all
HEMA modified surfaces (at the 200 μg/ml peptide concentration). The results showed a
significant decrease in spreading on HEMA modified surfaces (p=3.5×10–6). Nevertheless,
all surfaces caused the activation of paxillin protein, which indicated the binding or
engagement of integrin receptors with the underlying extracellular matrix. The area of cell
spreading on various modified Nafion™ surfaces was about 50% lower in comparison to
unmodified Nafion™ surfaces preadsorbed with 10% serum (Fig. 3). We also note from Fig.
8 that there is an increase in cell spreading as the coupled peptide concentration increases,
for all levels of HEMA treatment. This difference is statistically significant (p=0.0007). So,
in summary, the area of cell spreading that occurs in unmodified surfaces versus modified
surfaces is significantly different. The area of cell spreading that occurs on modified
surfaces is significantly higher on surface adsorbed with 200 μg/ml versus 20 μg/ml bulk
peptide concentration.
Proliferation assays were performed on unmodified Nafion™ surfaces (with and without
preadsorbed protein), a 10% HEMA Nafion™ modified surface reacted with 200 μg/ml
YRGDS peptide (as this was seen to yield the highest cell adhesion numbers), and a control
TCPS surface. The results of the proliferation assay, depicted in Fig. 9, show that all cells
were able to proliferate well on the unmodified Nafion™ (with 10% preadsorbed serum) and
on 10% HEMA modified Nafion™ surfaces, albeit not as efficiently as TCPS. Cells that
were plated on Nafion™ without protein adhered minimally and exhibited no considerable
proliferation. The Metra™ CICP procollagen peptide ELISA was used to quantify the
amount of type I collagen being secreted by NHDF in response to Nafion™ on unmodified
or modified surfaces and also as a result of possible biosensor chemical by-products. The
assay was performed as previously outlined and data are presented below as procollagen
peptides per cells (ng/cell) on the various surfaces. Figures 10 and 11 show collagen
propeptide production from cells on the unmodified and modified Nafion™ surfaces,
respectively (with a tenfold difference on the y-axis). For the most part, modified Nafion™
surfaces exhibited a tenfold decrease in the production of collagen molecules on a per cell
basis. The area of cell spreading was also quantified on these surfaces. In comparison to
unmodified Nafion™, there was a 40% reduction in cell spreading on 10% HEMA modified
Nafion™ surfaces. These results, displayed in Fig. 12, are based on cells that were examined
after 4 days of being in culture in blank serum-free media, which contained no extra
additives.
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In our previous work, the degree to which Nafion™ and modified Nafion™ surfaces
adsorbed proteins was analyzed as a function of the Nafion™ surface chemistry. Results
indicated that the least amount of proteins adsorbed onto surfaces that were “ether carbon”
rich versus surfaces displaying hydroxyl groups on the surface, which are also known to be
hydrophilic. Relating surface chemistry to cell behavior, we find that the amount and type of
protein that adsorbs to the surface will dictate cell behavior. Once pretreated with a protein,
such as fibronectin, or a 10% serum solution (both of which are known to adhere cells),
unmodified Nafion™ surfaces were able to adhere cells in a comparable fashion as the
control TCPS (~9000 cells/cm2 for both surfaces). In addition, Nafion™ surfaces
preadsorbed with protein were able to sustain the viability of NHDF, as well as provide a
satisfactory substratum for cell proliferation. Tetraglyme surfaces that adhered proteins to a
lower extent (protein mass/area) exhibited no cellular adhesion, as reported previously.105
Here, we observed that surfaces modified with 10% HEMA were not only able to maintain a
nonfouling substratum but also contained functional hydroxyl groups. The 10% HEMA
modified surfaces were also found to exhibit sufficient cell adhesion (6167 cells/cm2) and
the highest degree of cell spreading (0.002 mm2/cell at the 200 μg/ml bulk peptide
concentration) versus other HEMA modified surfaces. For these reasons, 10% HEMA
coated surfaces were examined more closely with proliferation assays,
immunocytochemistry, and type I procollagen ELISAs.
The intent of the surface bound peptide sequence, YRGDS, was to attract cells to an
otherwise nonfouling surface. Consequently, the number of YRGDS peptides per cell was
calculated. First, the number of peptides per surface area was calculated based on the
radiolabeled YRGDS. Ligands per cell were then calculated based on the area of cell
spreading. Table IV tabulates the number of ligands estimated per cell. There was a tenfold
increase in ligands attached to each cell as there was also a tenfold increase in the number of
YRGDS molecules attached at the higher bulk protein concentration. The values obtained
here are larger than the values obtained by Massia and Hubbell, in which a ligand cell
density of 1.2×104 was sufficient for integrin αvβ3-mediated fibroblast spreading and that
1.2×105 was necessary for the formation of focal contacts and stress fibers.113 It should be
noted that although the entire membrane was treated and the entire surface exposed to
peptide, it cannot be estimated at this time whether or not complete, uniform surface
coverage was reached. It was thought that the chances that a cell came in contact with a
peptide on the surface were quite high. However, the affinity of the cell to the peptide was
not measured as it was believed to be beyond the scope of this article. Cell affinity for the
modified surfaces may be dependent on a host of parameters, namely, time and location of
adhesion, interaction between cells, and cell physiology.
Modified Nafion™ surfaces displaying YRGDS peptide at different surface concentrations
did not necessarily correlate with an increase in cell spreading. Figure 13 shows the
relationship between cell spreading and the amount of peptide coupled to 2.5%, 5%, and
10% HEMA and pure HEMA surfaces. The y- and x-axes represent the average of cell
spreading and the average amount of YRGDS peptide bound, respectively, and therefore no
estimation of the standard error was carried out. A direct relationship is observed at lower
peptide concentration, with a threshold value of approximately 0.45 nmol/cm2 (60–65 ng/
cm2) YRDGS molecules linked at the surface for maximum cell spreading. However, at the
higher bulk peptide concentration, there is an inverse relationship between cell spreading
and peptide concentration for the 2.5%, 5%, and 10% HEMA modified surfaces. The same
trend was not observed for surfaces that were coated with pure HEMA. For these modified
surfaces, there appears to be an optimal concentration of bound peptide to promote
maximum cell spreading, which is approximately at 0.55 nmoles/cm2 of YRGDS peptide.
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Many studies have been conducted to understand how cell behavior is impacted by specific
ligand-integrin interactions. In particular, changes in cell shape/morphology can dictate cell
function by modulating integrin signaling pathways. As outlined by Boudreau and Jones,114
the blocking of the αvβ3 integrin has been found to result in the failure of endothelial cell
proliferation and survival if the cells are prevented from acquiring a spread morphology.
The authors postulated that cellular rounding leads to apoptosis due to decreased integrin
ligation, alluding to a change in cell signaling, as was also found by Chen et al.115 A
separate study, Chen et al. correlated the formation of focal adhesions (FAs) with the degree
to which a cell spreads and proposed that FA assembly scales directly with cell
spreading.116 Data presented here support this work, as it showed an apparent relationship
between cell spreading and the synthesis of procollagen molecules. Ivarsson et al.117 found
that the production of type I collagen in cultured human foreskin fibroblasts can be regulated
by cell spreading and by induction with platelet derived growth factor (PDFG-BB). Their
study found that type I collagen synthesis increased markedly in proportion to cell
spreading. Their findings correlate well with the results presented here using Nafion™ and
modified Nafion™ substrata.
IV. CONCLUSIONS
We found that type I collagen synthesis, known to be the main component of a fibrotic
capsule, can be modulated by (as shown by a tenfold reduction) presenting cells with a (1)
nonfouling substrata and (2) a bioactive peptide. This goal was accomplished via a plasma
deposition method in which two monomers were combined, creating a bioactive stealth
surface with tetraethylene glycol dimethyl ether (tetraglyme) and HEMA at predetermined
ratios. Surfaces containing hydroxyl groups were covalently bound to a YRGDS peptide,44
and cell viability, spreading, and proliferation activation of focal contacts were quantified in
addition to collagen synthesis. For the newly synthesized surfaces, there was an optimum
amount of YRGDS peptide that induced an optimal degree of cell spreading, affirming that
ligand density makes a difference in cell spreading, focal contact development, and
subsequent cell signaling pathways, thereby altering cellular response.117 This work shows
at least one potential strategy in the reduction of the fibrous capsule around implants,
thereby extending implant lifetime and viability.
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Fig. 1.
(Color online) Adherent NHDF cells (per cm2) on unmodified Nafion™ surfaces
preadsorbed with various proteins.
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Fig. 2.
(Color online) Typical cellular morphologies for NHDF on unmodified Nafion™ surfaces
and TCPS.
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Fig. 3.
(Color online) Area of NHDF spreading quantified on unmodified Nafion™ surfaces
preadsorbed with various proteins.
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Fig. 4.
(Color online) Adherent NHDF cells (per cm2) on various modified Nafion™ surfaces with
two different bulk peptide concentrations (actual surface concentrations unknown; only bulk
concentration reported; assumes a linear relationship).
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Fig. 5.
(Color online) Cells adhered on 10% HEMA surfaces with 200 μg/ml YRGDS vs number of
cells plated.
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Fig. 6.
(Color online) Typical cellular morphologies for NHDF on modified Nafion™ surfaces at
two different concentrations of YRGDS. Cells were allowed to adhere for 24 h.
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Fig. 7.
(Color online) Immunocytochemistry of NHDF on various substrata. “Merged” refers to an
overlay of actin and paxillin photographs.
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Fig. 8.
(Color online) Area of cell spreading on various modified Nafion™ surfaces.
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Fig. 9.
(Color online) Proliferation assay for NHDF on various Nafion™ surfaces.
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Fig. 10.
(Color online) Procollagen ELISA on unmodified Nafion™ surfaces. Results reported as
procollagen peptides per cell. Blank refers to serum-free media.
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Fig. 11.
(Color online) Procollagen ELISA on 10% HEMA modified Nafion™ surfaces. Results
reported as procollagen peptides per cell. There was no detectable collagen in Gox or H2O2
conditions. Blank refers to serum-free media.
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Fig. 12.
(Color online) Area of cell spreading quantified after 4 days of being in culture in blank
media.
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Fig. 13.
(Color online) Correlation between cell spreading and linked YRGDS at the various
modified Nafion™ surfaces.
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Table I
Biosensor by-products tested in the culture media for collagen type I synthesis.
Substance Source Concentration Ref.
Ascorbic acid Sigma A4544 50 μg/ ml 11
H2O2 Sigma H1009 20 μM Experimental, 12
Gox Fluka 49182 0.2 mU/ml 13
LPS Sigma 4391 3 μg/ ml 14
IL-1 Sigma I-9401 1 ng/ml 8
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Table II
Viability of cells adhered to unmodified Nafion™ surfaces via different proteins.
4 h 24 h
Protein % Live % Dead % Live % Dead
Fibronectin 96.8 ± 0.63 1.37 ± 0.64 99.37 ± 0.12 0.63 ± 0.12
Albumin 96.3 ± 2.4 3.72 ± 2.40 77.31 ± 4.61 12.02 ± 4.41
10% serum 96.8 ± 0.47 3.25 ± 0.47 92.95 ± 3.37 5.83 ± 3.97
TCPS (no protein) 89.47 ± 3.18 10.53 ± 3.17 85.78 ± 1.80 14.22 ± 1.80
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Table III
Viability of cells (± standard error of the mean) adhered to various HEMA modified Nafion™ surfaces via
YRGDS peptide at two different concentration (BC: bulk concentration).
YRGDS (BC=20 μg/ml) YRGDS (BC=200 μg/ml)
Surface % Live % Dead % Live % Dead
2.5% HEMA 95.24 ± 3.2 4.76 ± 3.2 90.1 ± 6.37 8.19 ± 6.37
5% HEMA 98.34 ± 1.6 1.65 ± 1.6 93.85 ± 5.8 6.14 ± 5.18
10% HEMA 97.09 ± 0.56 2.91 ± 0.56 94.45 ± 0.59 5.55 ± 0.59
HEMA 88.78 ± 1.14 11.21 ± 0.57 97.43 ± 1.43 2.5 ± 1.43
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Table IV
Calculated YRGDS molecules per cell for each of the modified surfaces (details provided in text).
Bulk YRGDS-20 μg / ml mole / μm2 Area of cell (μm2 / cell) Ligands/cell
2.5% HEMA 3.21 × 105 5.02 × 102 1.61 × 108
5% HEMA 5.63 × 105 8.50 × 102 4.79 × 108
10% HEMA 3.02 × 105 7.18 × 102 2.17 × 108
HEMA 2.09 × 106 8.75 × 102 1.83 × 109
Bulk YRGDS-200 μg / ml mole / μm2 Area of cell (μm2 / cell) Ligands/cell
2.5% HEMA 6.38 × 106 8.93 × 102 5.69 × 109
5% HEMA 3.63 × 106 1.49 × 103 5.39 × 109
10% HEMA 3.08 × 106 1.75 × 103 5.38 × 109
HEMA 8.21 × 106 1.22 × 103 9.99 × 109
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